Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2006-001641-33-DE
EUCTR2006-001641-33-DE
Active, not recruiting
Phase 1

Positronen-Emissionstomographie-gesteuerte Therapie aggressiver Non-Hodgkin-Lymphome (Positron emission tomography guided therapy of aggressive non-Hodgkin's lymphomas) - PETAL-Studie (PETAL trial)

niversitätsklinikum Essen0 sites696 target enrollmentApril 25, 2007
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsAggressive non-Hodgkin's lymphomas (first line therapy)Therapeutic area: Diseases [C] - Cancer [C04]
DrugsCarmubrisCisplatin medacEndoxanUdicilDexa-ratiopharmUrbason

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Aggressive non-Hodgkin's lymphomas (first line therapy)
Sponsor
niversitätsklinikum Essen
Enrollment
696
Status
Active, not recruiting
Last Updated
7 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 25, 2007
End Date
TBD
Last Updated
7 years ago
Study Type
Interventional clinical trial of medicinal product

Investigators

Sponsor
niversitätsklinikum Essen

Eligibility Criteria

Inclusion Criteria

  • •Diagnosis of aggressive non\-Hodgkin's lymphoma
  • •B cell type
  • •diffuse large B cell lymphoma including variants and subtypes
  • •follicular lymphoma grade 3
  • •T cell type
  • •anaplastic large T or 0 cell lymphoma
  • •angioimmunoblastic T cell lymphoma
  • •peripheral T cell lymphoma not otherwise specified
  • •intestinal T/NK cell lymphoma
  • •hepatosplenic gamma\-delta T cell lymphoma

Exclusion Criteria

  • •Burkitt's lymphoma
  • •Primary cerebral lymphoma
  • •Start of therapy before attempted inclusion (except pre\-phase therapy of the study protocol)
  • •Prior chemo\- and/or radiotherapy
  • •Other neoplastic diseases within the preceding 5 years (except carcinoma in situ or basal cell carcinoma of the skin)
  • •Active viral hepatitis, HIV infection or other uncontrolled infections
  • •Severe organ dysfunction not explained by the lymphoma precluding administration of chemotherapy according to the study protocol

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Positron emission tomography (PET) guided therapy of diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with or without high dose chemotherapy followed by autologous stem cell transplantation (HDC/ASCT)Diffuse large B-cell lymphoma
JPRN-UMIN000004420Japan Study Group for Cell Therapy and Transplantation68
Completed
Not Applicable
Positron Emission Tomography And Recovery following Revascularization: Outcomes and Cost-Effectiveness using F-18-fluorodeoxyglucose (FDG) PET in Severe Left Ventricular Dysfunction (PARR Phase 2)Coronary artery disease, LV dysfunction, congestive heart failureCirculatory SystemCoronary artery disease
ISRCTN00827330niversity of Ottawa Heart Institute (Canada)430
Recruiting
Not Applicable
Positron emission tomography with innovative laboratory techniques for improved risk and disease assessment in myelomaMyelomatosis10018865
NL-OMON53692niversiteit Antwerpen40
Completed
Not Applicable
Brain imaging of the adenosine A2A receptor in schizophrenia
ISRCTN05808181King's College London (UK)18
Not yet recruiting
Not Applicable
Positron Emission Tomography as a diagnostic tool in Unilateral Condylar Hyperplasia and comparison with bone scintigraphy, including SPECTTemporo-Mandibulaire Gewrichtgrowth of the temporo-mandibular jointUnilateral Condylar Hyperplasia
NL-OMON30174Vrije Universiteit Medisch Centrum6